The loss of PTEN function in human gliomas is very frequent, particularly in glioblastoma (GB), with PTEN protein loss reported in between 65 and 69% of cases and has been associated with tumor grade, immunosuppressive tumor microenvironment, decreased overall survival time, and resistance to chemotherapy or radiotherapy [14,15,16,17,18]. Here, PTEN is linked to central nervous system cancer.